人福医药(600079.SH)：氟比洛芬酯注射液获得药品注册证书

Core Viewpoint - The approval of the drug registration certificate for Fluorobiphenyl Injection by the National Medical Products Administration marks a significant milestone for the company, enhancing its product pipeline and enabling it to sell the drug in the domestic market [1] Company Summary - The company’s subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., holds 80% of the shares and has received the drug registration certificate for Fluorobiphenyl Injection [1] - Fluorobiphenyl Injection is a non-steroidal analgesic suitable for postoperative and cancer pain management, utilizing lipid microspheres as a drug carrier [1] - The approval is expected to have a positive impact on the company, contributing to its growth and market presence [1]